Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 34c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Eagle Pharmaceuticals Reports Second Quarter 2020 Results
August 10, 2020 6:50 AM EDT-- Q2 2020 net loss was ($0.02) per basic and diluted share and adjusted non-GAAP net income was $0.59 per basic and $0.57 per diluted share --
-- Anticipate launch of vasopressin, maintaining our 180-day market exclusivity --
-- CMS establishes unique J-code for PEMFEXY (pemetrexed for injection); FDA granted supplement approval for 500mg multiple-dose vial --
-- Received positive additional data for the Companys fulvestrant product candidate, EA-114, for HR-positive advanced breast cancer --
-- Received a Complete Response Letter for NDA for... More
